These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 12952752

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Thalidomide: an experience in therapeutic outcome and adverse reactions.
    Sharma NL, Sharma VC, Mahajan VK, Shanker V, Ranjan N, Gupta M.
    J Dermatolog Treat; 2007; 18(6):335-40. PubMed ID: 17852637
    [Abstract] [Full Text] [Related]

  • 4. Thalidomide: dermatological indications, mechanisms of action and side-effects.
    Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK.
    Br J Dermatol; 2005 Aug; 153(2):254-73. PubMed ID: 16086735
    [Abstract] [Full Text] [Related]

  • 5. Thalidomide and its dermatologic uses.
    Paghdal KV, Schwartz R.
    Acta Dermatovenerol Croat; 2007 Aug; 15(1):39-44. PubMed ID: 17433179
    [Abstract] [Full Text] [Related]

  • 6. Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
    Fabi SG, Hill C, Witherspoon JN, Boone SL, West DP.
    J Drugs Dermatol; 2009 Aug; 8(8):765-9. PubMed ID: 19663116
    [Abstract] [Full Text] [Related]

  • 7. Thalidomide in leprosy and some dermatological conditions--a review.
    Parikh DA, Maniar JK, Ganapati R.
    Indian J Lepr; 1985 Aug; 57(4):862-7. PubMed ID: 3915010
    [No Abstract] [Full Text] [Related]

  • 8. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood.
    Shannon EJ, Ejigu M, Haile-Mariam HS, Berhan TY, Tasesse G.
    Lepr Rev; 1992 Mar; 63(1):5-11. PubMed ID: 1569817
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Thalidomide and its dermatologic uses.
    Moraes M, Russo G.
    Am J Med Sci; 2001 May; 321(5):321-6. PubMed ID: 11370795
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Thalidomide: current and potential clinical applications.
    Calabrese L, Fleischer AB.
    Am J Med; 2000 Apr 15; 108(6):487-95. PubMed ID: 10781782
    [Abstract] [Full Text] [Related]

  • 16. Thalidomide levels in patients with erythema nodosum leprosum.
    Vieira JL, Valente Mdo S.
    Ther Drug Monit; 2009 Oct 15; 31(5):602-3. PubMed ID: 19704404
    [Abstract] [Full Text] [Related]

  • 17. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    de Carsalade GY, Achirafi A, Flageul B.
    Acta Leprol; 2003 Oct 15; 12(3):117-22. PubMed ID: 15040702
    [Abstract] [Full Text] [Related]

  • 18. Thalidomide: new preparation. For well-defined indications.
    Prescrire Int; 1998 Oct 15; 7(37):131-4. PubMed ID: 10848043
    [Abstract] [Full Text] [Related]

  • 19. Thalidomide in erythema nodosum leprosum (ENL).
    Bourdillon C.
    Lepr Rev; 1988 Jun 15; 59(2):184-5. PubMed ID: 3246930
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.